ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”) warrants to purchase 250,000 Common Stock (the “Offering”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Registration Rights Agreement (this “Agreement”) is made and entered into as of __________, 2023, by and among Oncotelic Therapeutics, Inc. (the “Company”), a Delaware corporation with offices at 29397 Agoura Road, Suite 107, Agoura Hills, California 91301, and the investors signatories hereto (each a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated as of the date hereof, executed by each of the Purchasers and the Company (the “Subscription Agreement”).
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement and Investment Letter • July 13th, 2023 • Oncotelic Therapeutics, Inc. • Pharmaceutical preparations
This Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Oncotelic Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 10 and a maximum of 200 Units (the “Units”), each of which consists of one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00 for a period of 2 years from the date of final closing of the Offering, bearing annual interest at the rate of 16%. Each Note will be convertible into 250,000 shares of Oncotelic’s Common Stock (conversion price $0.10 per share), subject to applicable anti dilution provisions. Each Unit will also consist of 250,000 (the “Warrants”), each to purchase one share of Oncotelic’s Common Stock at $0.12 per share. The exercise price of
